From an industry that shouts at every doctor to one that reaches the right physician at the right moment — a look inside the effort to cut through the noise so life-changing information actually arrives in time.

Medicine has never moved faster. New studies, therapies, clinical trials, and treatment guidelines emerge constantly, especially in oncology and rare disease, and no physician can absorb it all while caring for patients and drowning in paperwork. The consequence is quiet but serious: the newest, best option for a patient may already exist, and the doctor in the room simply has not gotten to it yet. It can take an average of seventeen years for proven research to reach everyday practice [CONFIRM STAT], and for a patient with a fast-moving disease, that gap can be measured in lives.

Hemal Somaiya has spent more than fifteen years inside that system, with leadership roles at Merck, AstraZeneca, and Boston Scientific and consulting work through IQVIA, and today she serves as Chief Executive & Strategy Officer of PharmaForceIQ. That vantage is what convinced her the traditional model was broken: an industry built for the blockbuster era, shouting at every doctor at maximum volume, at the very moment medicine was fragmenting into specialized therapies for smaller groups of patients.

PharmaForceIQ is her answer. It is an AI platform built for life sciences that replaces indiscriminate, high-volume marketing with what the industry calls an “optichannel” approach: the right channel, timing, and message for an individual physician, with digital and field teams coordinated so doctors get one consistent experience instead of a dozen conflicting ones. Reading aggregated, privacy-compliant real-world signals rather than patient data, it can surface a nearby clinical trial or a new treatment option and get it to the right physician within 24 to 48 hours. Somaiya was named a 2025 MM+M Woman of Distinction and a PM360 ELITE 100 “Disrupter,” and in early 2026 PharmaForceIQ acquired the AI engagement company Aktana.

For the patients and caregivers fighting for the best possible care, for the physicians buried under more information than any person could manage, for the pharmaceutical leaders rethinking how they reach doctors, and for the investors watching AI remake healthcare, this is the segment to watch.